Form 4: Kymera Therapeutics CFO Exercises Stock Options and Reports Beneficial Ownership

Bruce N. Jacobs, CFO of Kymera Therapeutics, reports exercising stock options and updating his beneficial ownership of company stock.

Summary

• On June 27, 2024, Bruce N. Jacobs, the Chief Financial Officer of Kymera Therapeutics, exercised stock options to acquire 25,000 shares of common stock at a price of $2.08 per share.
• Following this transaction, Jacobs directly owns 168,554 shares of Kymera Therapeutics common stock.
• Jacobs also directly owns options for 104,899 shares.
• The reported transactions include 1,203 shares acquired under the employee stock purchase plan on June 1, 2024.
• The stock options vest over time, with 25% vesting on July 1, 2020, and the remaining shares vesting in equal monthly installments over 36 months, contingent upon continued employment.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option exercises and doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The CFO's exercise of stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the stock options implies a continued commitment from the CFO.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their ownership positions. This filing is specific to Kymera Therapeutics and its CFO.

Stakeholder Impact

• Shareholders may view the CFO's stock option exercise as a sign of confidence in the company.
• The transaction has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates